

Tanta University

Faculty of Medicine

Clinical Oncology Department

M.Sc. Exam 1st part

Clinical Oncology & Nuclear Medicine

Optional Determinant 23/ 3/ 2021

All questions should be answered:

	Marks
Q1. The classification and the rational of topoisomerase inhibitors?	20
Q2. Mention the classification and the rational of antimetabolites?	20
Q3. <u>Choose the correct answer:</u>	5
1. Dose of cetuximab in metastatic Colorectal cancer,	
a. Initial loading dose: 400 mg/m ² infused over 120 minutes AND Maintenance dose: 250 mg/m ² infused over 60 minutes weekly until disease progression or unacceptable toxicity	
b. Initial loading dose: 500 mg/m ² infused over 120 minutes AND Maintenance dose: 200 mg/m ² infused over 60 minutes weekly until disease progression or unacceptable toxicity	
c. Initial loading dose: 300 mg/m ² infused over 120 minutes AND Maintenance dose: 150 mg/m ² infused over 60 minutes weekly until disease progression or unacceptable toxicity	
d. Initial loading dose: 600 mg/m ² infused over 120 minutes AND Maintenance dose: 300 mg/m ² infused over 60 minutes weekly until disease progression or unacceptable toxicity	
2. bevacizumab dose in metastatic Colorectal cancer in combination with fluorouracil-based chemotherapy (initially treated)	
a. 7.5 mg/kg every 2 weeks	
b. IV: 5 mg/kg every 2 weeks (in combination with FOLFOX4)	

- c. 10 mg/kg every 2 weeks (in combination with bolus-IFL).
- d. 10 mg/kg every 2 weeks (in combination with FOLFOX4).

3. Neuropathy with oxaliplatin is

- a. A dose-limiting side effect
- b. NOT cumulative,
- c. Occurs with increasing frequency above doses of 300 mg/m²
- d. Does not require drug discontinuation if there is tumor response

4. Irinotecan is

- a. Dose of irinotecan in Colorectal cancer, metastatic (single-agent therapy): Weekly regimen: 200 mg/m² over 90 minutes on days 1, 8, 15, and 22 of a 6-week treatment cycle
- b. neuropathy is a dose limiting side effect with irinotecan
- c. Antineoplastic Agent, Topoisomerase I Inhibitor
- d. antimetabolite cytotoxic agent

5. capecitabine is

- a. Antineoplastic Agent, Antimetabolite
- b. XELOX less toxic than FOLFOX
- c. Capecitabine -irinotecan combination is standard
- d. Alkylating agent

Good luck